Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?

被引:8
作者
Mitsala, Athanasia [1 ]
Tsalikidis, Christos [1 ]
Romanidis, Konstantinos [1 ]
Pitiakoudis, Michail [1 ]
机构
[1] Democritus Univ, Univ Gen Hosp Alexandroupolis, Dept Surg 2, Thrace Med Sch, Dragana 68100, Alexandroupolis, Greece
关键词
non-alcoholic fatty liver disease; colorectal adenomas; colorectal cancer; extrahepatic cancers; metabolic syndrome; insulin resistance; MORBIDLY OBESE-PATIENTS; BODY-MASS INDEX; MAGNETIC-RESONANCE ELASTOGRAPHY; CLINICAL-PRACTICE GUIDELINES; INSULIN-RESISTANCE; HEPATIC STEATOSIS; GASTRIC BYPASS; INCREASED RISK; ASYMMETRIC DIMETHYLARGININE; METABOLIC ABNORMALITIES;
D O I
10.3390/curroncol29070356
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is now considered the main driver and leading cause of chronic liver disease globally. The umbrella term NAFLD describes a range of liver conditions closely related to insulin resistance, metabolic syndrome, diabetes mellitus, obesity, and dyslipidemia. At the same time, several malignancies, including hepatocellular carcinoma and colorectal cancer, are considered to be common causes of death among patients with NAFLD. At first, our review herein aims to investigate the role of NAFLD in developing colorectal neoplasms and adenomatous polyps based on the current literature. We will also explore the connection and the missing links between NAFLD and extrahepatic cancers. Interestingly, any relationship between NAFLD and extrahepatic malignancies could be attributable to several shared metabolic risk factors. Overall, obesity, insulin resistance, metabolic syndrome, and related disorders may increase the risk of developing cancer. Therefore, early diagnosis of NAFLD is essential for preventing the progression of the disease and avoiding its severe complications. In addition, cancer screening and early detection in these patients may improve survival and reduce any delays in treatment.
引用
收藏
页码:4478 / 4510
页数:33
相关论文
共 242 条
  • [51] Steatohepatitis: A tale of two "hits"?
    Day, CP
    James, OFW
    [J]. GASTROENTEROLOGY, 1998, 114 (04) : 842 - 845
  • [52] Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role
    De Lorenzo, Stefania
    Tovoli, Francesco
    Mazzotta, Alessandro
    Vasuri, Francesco
    Edeline, Julien
    Malvi, Deborah
    Boudjema, Karim
    Renzulli, Matteo
    Jeddou, Heithem
    D'Errico, Antonietta
    Turlin, Bruno
    Cescon, Matteo
    Uguen, Thomas
    Granito, Alessandro
    Lievre, Astrid
    Brandi, Giovanni
    [J]. CANCERS, 2020, 12 (11) : 1 - 14
  • [53] Nonalcoholic fatty liver disease - current status and future directions
    Demir, Muenevver
    Lang, Sonja
    Steffen, Hans-Michael
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2015, 16 (10) : 541 - 557
  • [54] MCD diet-induced steatohepatitis is associated with alterations in asymmetric dimethylarginine (ADMA) and its transporters
    Di Pasqua, Laura G.
    Berardo, Clarissa
    Rizzo, Vittoria
    Richelmi, Plinio
    Croce, Anna Cleta
    Vairetti, Mariapia
    Ferrigno, Andrea
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 2016, 419 (1-2) : 147 - 155
  • [55] Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
    Dixon, JB
    Bhathal, PS
    O'Brien, PE
    [J]. GASTROENTEROLOGY, 2001, 121 (01) : 91 - 100
  • [56] Elevated asymmetric dimethylarginine in plasma: An early marker for endothelial dysfunction in non-alcoholic fatty liver disease?
    Dogru, Teoman
    Genc, Halil
    Tapan, Serkan
    Ercin, Cemal Nuri
    Ors, Fatih
    Aslan, Fatih
    Kara, Muammer
    Sertoglu, Erdim
    Bagci, Sait
    Kurt, Ismail
    Sonmez, Alper
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 96 (01) : 47 - 52
  • [57] Statin use and non-alcoholic steatohepatitis in at risk individuals
    Dongiovanni, Paola
    Petta, Salvatore
    Mannisto, Ville
    Mancina, Rosellina Margherita
    Pipitone, Rosaria
    Karja, Vesa
    Maggioni, Marco
    Kakela, Pirjo
    Wiklund, Olov
    Mozzi, Enrico
    Grimaudo, Stefania
    Kaminska, Dorota
    Rametta, Raffaela
    Craxi, Antonio
    Fargion, Silvia
    Nobili, Valerio
    Romeo, Stefano
    Pihlajamaki, Jussi
    Valenti, Luca
    [J]. JOURNAL OF HEPATOLOGY, 2015, 63 (03) : 705 - 712
  • [58] Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
    Eguchi, Yuichiro
    Kitajima, Yoichiro
    Hyogo, Hideyuki
    Takahashi, Hirokazu
    Kojima, Motoyasu
    Ono, Masafumi
    Araki, Norimasa
    Tanaka, Kenichi
    Yamaguchi, Miyuki
    Matsuda, Yayoi
    Ide, Yasushi
    Otsuka, Taiga
    Ozaki, Iwata
    Ono, Naofumi
    Eguchi, Takahisa
    Anzai, Keizo
    [J]. HEPATOLOGY RESEARCH, 2015, 45 (03) : 269 - 278
  • [59] Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study
    Eguchi, Yuichiro
    Hyogo, Hideyuki
    Ono, Masafumi
    Mizuta, Toshihiko
    Ono, Naofumi
    Fujimoto, Kazuma
    Chayama, Kazuaki
    Saibara, Toshiji
    [J]. JOURNAL OF GASTROENTEROLOGY, 2012, 47 (05) : 586 - 595
  • [60] Long-term follow-up of patients with NAFLD and elevated liver enzymes
    Ekstedt, Mattias
    Franzen, Lennart E.
    Mathiesen, Ulrik L.
    Thorelius, Lars
    Holmqvist, Marika
    Bodemar, Goran
    Kechagias, Stergios
    [J]. HEPATOLOGY, 2006, 44 (04) : 865 - 873